A study found that dexrazoxane, a cardioprotective drug, preserved cardiac function without compromising overall survival and event-free survival for pediatric patients with acute myeloid leukemia.
The FDA granted priority review to a new drug application for CC-486 for the maintenance treatment of adult patients with acute myeloid leukemia based on efficacy and safety results from the pivotal phase III QUAZAR AML-001 study.
The International Lymphoma Radiation Oncology Group laid out a set of emergency recommendations for alternative radiation treatment schemes for treating patients with hematologic malignancies during the COVID-19 pandemic.
Genentech recently announced their phase III study resulted in improved overall survival and composite complete remission rates for patients with previously untreated acute myeloid leukemia.
Hematopoietic stem cell transplantation (HSCT) with prior use of checkpoint inhibitors was found to be feasible in patients with acute myeloid leukemia and/or myelodysplastic syndromes and the use of post-HSCT cyclophosphamide as graft-versus host disease prophylaxis improves outcomes.
The planned trial will investigate the safety and efficacy of the novel multi-tumor associated antigen T-cell therapy in patients with post-transplant acute myeloid leukemia.
Naval Daver, MD, explains the progress made on 3 abstracts he’s involved with regarding acute myeloid leukemia (AML) at the ASH Annual Meeting and Exposition.
Researchers developed a risk score assessment to measure potential risk for chemotherapy-induced heart failure
Courtney DiNardo, MD, MSCE, elaborated on interim phase II results regarding enasibenib plus azacitidine in patients with newly diagnosed acute myeloid leukemia, and the results from the QUAZAR trial.
The study evaluating itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease did not produce statistically significant results.